Rocket sells priority review voucher for $180M after Kresladi gene therapy approval

Who is this relevant for?

• Pharmaceutical buyers sourcing shortage medicines
• Manufacturers evaluating market entry
• Distributors monitoring sourcing opportunities

Rocket Pharmaceuticals sold a priority review voucher (PRV) for $180 million following the FDA approval of its gene therapy Kresladi. The sale underscores the financial value of rare disease regulatory incentives.

Rocket earned the PRV under the Rare Pediatric Disease Priority Review Voucher program after Kresladi received approval. The voucher can be used to expedite FDA review of another drug, or sold. This transaction shows how companies can monetize regulatory incentives to fund operations or pipeline development.

For buyers and distributors, the sale highlights potential supply chain shifts. Companies that acquire PRVs may accelerate product launches, affecting market entry timing. Manufacturers evaluating the US market should note the role of these vouchers in commercialization strategy.

Rocket's deal demonstrates that rare disease approvals carry value beyond the drug itself. The PRV market remains active, and this $180 million sale reinforces the incentive structure for developing treatments for small patient populations.